Disclosures and Reports. A. The User shall furnish the Patent Counsel a written report containing full and complete technical information concerning each Subject Invention it makes within 6 months after conception or first actual reduction to practice, whichever occurs first, in the course of or under this Agreement, but in any event prior to any on sale, public use, or public disclosure of such invention known to the User. The report shall identify the contract and inventor and shall be sufficiently complete in technical detail and appropriately illustrated by sketch or diagram to convey to one skilled in the art to which the invention pertains a clear understanding, to the extent known at the time of disclosure, of the nature, purpose, operation, and the physical, chemical, biological, or electrical characteristics of the invention. The report should also include any election of invention rights under this article. When an invention is reported under this paragraph 4.A, it shall be presumed to have been made in the manner specified in Section (a)(1) and (2) of 42 USC 5908.
Disclosures and Reports. During the Term, each Party shall promptly disclose to the other in writing all Program Technology generated by such Party, which disclosure shall be in sufficient detail to permit the other Party to employ such Program Technology as provided herein. Within [***] of the termination or expiration of this Agreement, each Party shall provide the other Party with a comprehensive final written report with respect to the Program Technology generated by such Party under this Agreement. ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under
Disclosures and Reports. During the Collaboration Term, each Party shall promptly disclose to the other in writing all Know-How generated in the course of the Collaboration. Such disclosure shall be in sufficient detail to permit the other Party to employ such Know-How as provided herein. Within ninety (90) days after completion of the Collaboration, each Party shall provide the other Party with a comprehensive final written report with respect to the Know-How generated by such Party in the course of the Collaboration.
Disclosures and Reports. Phytera and Lilly shall disclose to one another promptly the results achieved in conducting the Program and all Program Technology developed in the Program. Disclosure shall be in sufficient detail to permit each Party to employ such results and Program Technology as provided herein. Such disclosures may take the form of limited visits by Lilly and Phytera personnel to the facilities being utilized for the Program to permit observation of the procedures being employed pursuant to Section 2.17. While the Program is being conducted, the Research Team shall submit to Phytera and Lilly a detailed written quarterly report on the progress of the Program. Within ninety (90) days after completion of the Program, the Research Team shall provide Phytera and Lilly with a comprehensive final written report. (B)
Disclosures and Reports shall keep Pisa informed of all uses that makes of the Materials. shall submit a final written report to Pisa within thirty (30) days of the completion of the Research, which report shall include a summary of the Results as specifically listed in the Schedule 2 - Research. acknowledges and agrees that Pisa has the right to independently use or in any way exploit these Results.
Disclosures and Reports. USER shall provide through the iEdison reporting system, unless otherwise directed by Patent Counsel, a written report concerning each USER Subject Invention, which includes inventions of any Participants, within six months after conception or first actual reduction to practice, whichever occurs first. If USER wishes to elect title to the Subject Invention, a notice of election to the Subject Invention should be submitted with the report or within one year of such date of reporting of the Subject Invention.
Disclosures and Reports. Reports . Recipient shall keep AstraZeneca informed of all uses that Recipient makes of the Materials. During the term of this Agreement, Recipient shall, and shall require the Researchers to, prepare and submit written progress reports to AstraZeneca within thirty (30) days of the end of each calendar quarter. Such report(s) shall include all Results achieved during the relevant period including, for the avoidance of doubt, all raw data resulting from studies conducted in the course of the Research. Recipient shall, and shall require the Researchers to, prepare and submit a final written report to AstraZeneca within thirty (30) days of the expiration or earlier termination of this Agreement, which report shall include a comprehensive summary of the Research undertaken, all Results, and any other accomplishments achieved in connection with such Research. All reports submitted under this Section 4.1 shall be prepared in accordance with the requirements specified in Section 4.2 and any other instructions provided by AstraZeneca. Recordkeeping . All Research Documentation shall be complete, current, accurate, organized and legible, and shall be prepared and maintained in a manner acceptable for the collection of data for submission to, or review by, regulatory authorities and in full compliance with all applicable laws. The Recipient shall cause each Researcher to maintain the Research Documentation separate from all other records kept by each such Researcher. Without limiting the generality of the foregoing, such Research Documentation shall provide at least the level of detail necessary to support the filing and prosecution of patent applications for any inventions discovered, created, conceived or reduced to practice in the conduct of the Research. Ownership of Results and Materials Background Intellectual Property . For the avoidance of doubt, all intellectual property and know-how existing as of the Effective Date, or developed or acquired outside of the scope of this Agreement (“Background Intellectual Property”), that is used in connection with the Research shall remain the property of the Party introducing the same. Nothing in this Agreement shall transfer any rights in such Background Intellectual Property to the other Party. In the event that a license to certain Background Intellectual Property owned by Recipient is necessary for AstraZeneca to develop or exploit commercially any Results, and if Recipient is able to grant AstraZeneca rights in such...
Disclosures and Reports. Recipient shall keep AstraZeneca informed of all uses that Recipient makes of the Materials. Recipient shall submit a final written report to AstraZeneca within thirty (30) days of the expiration or earlier termination of this Agreement, which report shall include a comprehensive summary of the Research undertaken, any Results (ncluding, for the avoidance of doubt, all raw data resulting from studies conducted in the course of the Research) nd any other accomplishments achieved in connection with such Research.
Disclosures and Reports
